NCT06793163 Diagnosis and Allergen Identification of Perioperative Anaphylaxis
| NCT ID | NCT06793163 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Peking University First Hospital |
| Condition | Perioperative/Postoperative Complications |
| Study Type | OBSERVATIONAL |
| Enrollment | 115 participants |
| Start Date | 2025-01-25 |
| Primary Completion | 2027-12 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 115 participants in total. It began in 2025-01-25 with a primary completion date of 2027-12.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Perioperative anaphylaxis may lead to fatal respiratory and/or circulatory events, yet both clinical diagnosis and management are challenging. Serum tryptase is an indicator that can provide important retrospective diagnostic value for anaphylaxis. Another key point in perioperative anaphylaxis management is to identify the allergens, and thus avoid re-exposure during later perioperative management. Skin testing is an important way to identify allergens.
Eligibility Criteria
Inclusion Criteria: * Aged 2 years or over; * Suspected anaphylaxis in the operating rooms, or history of suspected anaphylaxis in the operating room. Exclusion Criteria: * Refuse to participate; * Other conditions that are considered unsuitable for study participation.
Contact & Investigator
Dong-Xin Wang, MD, PhD
PRINCIPAL INVESTIGATOR
Peking University First Hospital
Frequently Asked Questions
Who can join the NCT06793163 clinical trial?
This trial is open to participants of all sexes, aged 2 Years or older, studying Perioperative/Postoperative Complications. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06793163 currently recruiting?
Yes, NCT06793163 is actively recruiting participants. Contact the research team at wangdongxin@hotmail.com for enrollment information.
Where is the NCT06793163 trial being conducted?
This trial is being conducted at Beijing, China, Beijing, China, Beijing, China, Beijing, China and 1 additional location.
Who is sponsoring the NCT06793163 clinical trial?
NCT06793163 is sponsored by Peking University First Hospital. The principal investigator is Dong-Xin Wang, MD, PhD at Peking University First Hospital. The trial plans to enroll 115 participants.